Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

NCT04989855 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG: Fruquintinib plus Tislelizumab

Sponsor

Sun Yat-sen University